Saxenda contains liraglutide, an older-generation GLP-1 receptor agonist. Like Wegovy and Mounjaro, it mimics the GLP-1 gut hormone to reduce appetite, slow gastric emptying, and regulate blood sugar. It was one of the first GLP-1 medications to be licensed specifically for weight management in the UK.
The main practical difference from newer options is that Saxenda requires a daily injection rather than a weekly one, and it produces less weight loss on average (~8% vs 20%+ for Mounjaro and Wegovy). For this reason, Saxenda is increasingly being replaced by the newer weekly medications, though it remains a valid option for people who prefer it or who don't tolerate the alternatives.
Saxenda is titrated weekly (faster than the monthly escalation of Mounjaro and Wegovy):
If you experience significant side effects at a dose, your prescriber may keep you at a lower dose for longer before increasing.
Licensed for: Weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.1
NHS: Available through Tier 3 specialist weight management services.
Private: Available from most online prescribers with similar BMI criteria.
Serious risks include pancreatitis (~1 in 100) and gallbladder disease.1
View full side effects breakdown →
SCALE programme: The pivotal trial showed liraglutide 3.0mg produced an average weight loss of approximately 8% of body weight over 56 weeks, with 63% of participants losing at least 5%.2
Private prescriptions for Saxenda typically cost £150–£230 per month. This is broadly comparable to Mounjaro and cheaper than Wegovy, though the lower average weight loss means the cost-per-outcome may be less favourable.
This page is for informational purposes only. Saxenda is a prescription-only medicine. Always consult a qualified healthcare professional.